PCSK9 Inhibitor Use in Heart Transplant Recipients: A Case Series and Review of the Literature

Transplantation. 2020 Jan;104(1):e38-e39. doi: 10.1097/TP.0000000000002944.

Authors

Douglas L Jennings^{1

2}, Ruslana Jackson³, Maryjane Farr³

Affiliations

¹ Department of Pharmacy Practice, Long Island University, New York, NY.
² Department of Pharmacy, New York-Presbyterian Hospital Columbia University Medical Center, New York, NY.
³ Division of Cardiology, Department of Medicine, NewYork-Presbyterian Hospital, Columbia University, New York, NY.

PMID: 31478991
DOI: 10.1097/TP.0000000000002944

No abstract available

Publication types

Letter
Review

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Humanized / pharmacology
Antibodies, Monoclonal, Humanized / therapeutic use
Anticholesteremic Agents / pharmacology
Anticholesteremic Agents / therapeutic use*
Calcineurin Inhibitors / pharmacology
Calcineurin Inhibitors / therapeutic use
Drug Interactions
Female
Follow-Up Studies
Graft Rejection / blood
Graft Rejection / immunology
Graft Rejection / prevention & control*
Heart Transplantation / adverse effects*
Humans
Hydroxymethylglutaryl-CoA Reductase Inhibitors / pharmacology
Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use
Immunosuppressive Agents / pharmacology
Immunosuppressive Agents / therapeutic use*
Lipoproteins, LDL / blood
Lipoproteins, LDL / metabolism
Male
Middle Aged
PCSK9 Inhibitors*
Proprotein Convertase 9 / metabolism
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Anticholesteremic Agents
Calcineurin Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Immunosuppressive Agents
Lipoproteins, LDL
PCSK9 Inhibitors
PCSK9 protein, human
Proprotein Convertase 9
evolocumab
alirocumab